Please login to the form below

Not currently logged in
Email:
Password:

Bulgarian pharma industry to strike over price cuts

The Bulgarian pharmaceutical industry is poised to strike over proposed price decreases in the new regulations for the registration and prices of medication

The Bulgarian pharmaceutical industry is poised to strike over proposed price decreases in the new regulations for the registration and prices of medication, according to local media reports.

The Bulgarian Pharmaceutical Union (BFU) claimed in an 11 November announcement on Bulgarian National Radio that lower prices would lead to the bankruptcy of pharmacies.

Head of the Pharmaceutical Group of the European Union (PGEU), Leopold Schmudermaier, will visit Bulgaria on 24 November for a special conference of the BFU, the union revealed.

Schmudermaier had sent an open letter to the Bulgarian health ministry, which criticised the new regulation. He claimed that lower prices would lead to lower quality pharmaceutical services and problematic access to medication for patients because of bankruptcies of pharmacies, caused by the proposed price decreases.

The BFU said in a press statement that it was categorically against the proposed cut in surplus charges for pharmacies over the distribution and sales of medication.

It added: "At the November BFU conference, rules and regulations for good pharmaceutical practise were set. Following these rules would become impossible, if Parliament accepts the current proposal, as pharmacies would not be able to afford to do so."

30th September 2008

Share

Subscribe to our email news alerts

PMHub

Add my company
fox&cat

Fox&cat is an award-winning healthcare communications agency which creates inspirational campaigns and programmes that exceed expectations. Priding itself on delivering...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...